Logo image of AXSM

AXSOME THERAPEUTICS INC (AXSM) Stock Fundamental Analysis

NASDAQ:AXSM - Nasdaq - US05464T1043 - Common Stock - Currency: USD

137.75  +8.65 (+6.7%)

After market: 138.951 +1.2 (+0.87%)

Fundamental Rating

2

Taking everything into account, AXSM scores 2 out of 10 in our fundamental rating. AXSM was compared to 194 industry peers in the Pharmaceuticals industry. The financial health of AXSM is average, but there are quite some concerns on its profitability. AXSM is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

AXSM had negative earnings in the past year.
AXSM had a negative operating cash flow in the past year.
AXSM had negative earnings in each of the past 5 years.
AXSM had a negative operating cash flow in each of the past 5 years.
AXSM Yearly Net Income VS EBIT VS OCF VS FCFAXSM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

AXSM has a Return On Assets of -50.52%. This is in the lower half of the industry: AXSM underperforms 62.70% of its industry peers.
With a Return On Equity value of -503.76%, AXSM is not doing good in the industry: 81.62% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -50.52%
ROE -503.76%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AXSM Yearly ROA, ROE, ROICAXSM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K

1.3 Margins

The Gross Margin of AXSM (91.37%) is better than 94.59% of its industry peers.
The Profit Margin and Operating Margin are not available for AXSM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 91.37%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AXSM Yearly Profit, Operating, Gross MarginsAXSM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

4

2. Health

2.1 Basic Checks

AXSM does not have a ROIC to compare to the WACC, probably because it is not profitable.
AXSM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
AXSM Yearly Shares OutstandingAXSM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
AXSM Yearly Total Debt VS Total AssetsAXSM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

2.2 Solvency

AXSM has an Altman-Z score of 4.65. This indicates that AXSM is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of AXSM (4.65) is better than 78.92% of its industry peers.
A Debt/Equity ratio of 3.22 is on the high side and indicates that AXSM has dependencies on debt financing.
AXSM's Debt to Equity ratio of 3.22 is on the low side compared to the rest of the industry. AXSM is outperformed by 84.86% of its industry peers.
Industry RankSector Rank
Debt/Equity 3.22
Debt/FCF N/A
Altman-Z 4.65
ROIC/WACCN/A
WACC9.92%
AXSM Yearly LT Debt VS Equity VS FCFAXSM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

2.3 Liquidity

A Current Ratio of 2.11 indicates that AXSM has no problem at all paying its short term obligations.
AXSM's Current ratio of 2.11 is in line compared to the rest of the industry. AXSM outperforms 41.62% of its industry peers.
AXSM has a Quick Ratio of 2.04. This indicates that AXSM is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.04, AXSM perfoms like the industry average, outperforming 45.95% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.11
Quick Ratio 2.04
AXSM Yearly Current Assets VS Current LiabilitesAXSM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for AXSM have decreased by -4.04% in the last year.
The Revenue has grown by 42.53% in the past year. This is a very strong growth!
EPS 1Y (TTM)-4.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.85%
Revenue 1Y (TTM)42.53%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%66.04%

3.2 Future

AXSM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 40.13% yearly.
AXSM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 44.56% yearly.
EPS Next Y55.5%
EPS Next 2Y58.41%
EPS Next 3Y55.9%
EPS Next 5Y40.13%
Revenue Next Year64.72%
Revenue Next 2Y64.36%
Revenue Next 3Y57.57%
Revenue Next 5Y44.56%

3.3 Evolution

AXSM Yearly Revenue VS EstimatesAXSM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B
AXSM Yearly EPS VS EstimatesAXSM Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 10 20

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

AXSM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year AXSM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AXSM Price Earnings VS Forward Price EarningsAXSM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AXSM Per share dataAXSM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6

4.3 Compensation for Growth

AXSM's earnings are expected to grow with 55.90% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y58.41%
EPS Next 3Y55.9%

More info and screens

0

5. Dividend

5.1 Amount

AXSM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AXSOME THERAPEUTICS INC

NASDAQ:AXSM (2/21/2025, 8:02:31 PM)

After market: 138.951 +1.2 (+0.87%)

137.75

+8.65 (+6.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-18 2025-02-18/bmo
Earnings (Next)05-05 2025-05-05/bmo
Inst Owners75.65%
Inst Owner Change-90.65%
Ins Owners1.43%
Ins Owner Change0.56%
Market Cap6.68B
Analysts85.45
Price Target158.67 (15.19%)
Short Float %14.17%
Short Ratio6
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.08%
Min EPS beat(2)6.83%
Max EPS beat(2)7.32%
EPS beat(4)2
Avg EPS beat(4)-6.49%
Min EPS beat(4)-22.89%
Max EPS beat(4)7.32%
EPS beat(8)3
Avg EPS beat(8)-6.96%
EPS beat(12)5
Avg EPS beat(12)-5.09%
EPS beat(16)9
Avg EPS beat(16)-1.18%
Revenue beat(2)1
Avg Revenue beat(2)1.38%
Min Revenue beat(2)-1.02%
Max Revenue beat(2)3.79%
Revenue beat(4)2
Avg Revenue beat(4)0.35%
Min Revenue beat(4)-1.69%
Max Revenue beat(4)3.79%
Revenue beat(8)6
Avg Revenue beat(8)34.29%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)18.35%
PT rev (3m)21.41%
EPS NQ rev (1m)-9.07%
EPS NQ rev (3m)-23.43%
EPS NY rev (1m)-13.22%
EPS NY rev (3m)-9.1%
Revenue NQ rev (1m)0.71%
Revenue NQ rev (3m)3.88%
Revenue NY rev (1m)-1.82%
Revenue NY rev (3m)0.32%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 17.31
P/FCF N/A
P/OCF N/A
P/B 117.08
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-5.41
EYN/A
EPS(NY)-2.41
Fwd EYN/A
FCF(TTM)-2.66
FCFYN/A
OCF(TTM)-2.65
OCFYN/A
SpS7.96
BVpS1.18
TBVpS-0.04
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -50.52%
ROE -503.76%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 91.37%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.68
Health
Industry RankSector Rank
Debt/Equity 3.22
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3.39%
Cap/Sales 0.07%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.11
Quick Ratio 2.04
Altman-Z 4.65
F-Score3
WACC9.92%
ROIC/WACCN/A
Cap/Depr(3y)9.27%
Cap/Depr(5y)133.06%
Cap/Sales(3y)0.56%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-4.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.85%
EPS Next Y55.5%
EPS Next 2Y58.41%
EPS Next 3Y55.9%
EPS Next 5Y40.13%
Revenue 1Y (TTM)42.53%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%66.04%
Revenue Next Year64.72%
Revenue Next 2Y64.36%
Revenue Next 3Y57.57%
Revenue Next 5Y44.56%
EBIT growth 1Y-21.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year106.08%
EBIT Next 3Y58.02%
EBIT Next 5Y43.28%
FCF growth 1Y11.66%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.49%
OCF growth 3YN/A
OCF growth 5YN/A